Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5697764 | 1.00 | TNFRSF1A (0.81) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL21446883 | 0.92 | TNFRSF1A (0.73) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL30383266 | 0.90 | TNFRSF1A (1.00) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL3215700 | 0.90 | TNFRSF1A (1.00) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL3215707 | 0.90 | TNFRSF1A (1.00) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL30674925 | 0.90 | TNFRSF1A (1.00) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL6779204 | 0.89 | TNFRSF1A (0.77) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL6779194 | 0.89 | TNFRSF1A (0.77) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL7198465 | 0.89 | MAPT (0.82) | TNFRSF1AMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL7198467 | 0.89 | MAPT (0.82) | TNFRSF1AMAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284952-B1 | SUBSTITUTED CHALCONES AS THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2006-06-21 | — | — | EP | disclosed |
| US-6787672-B2 | 1-(4-METHOXYPHENYL)-3-(3,5-DIMETHOXYPHENYL)PROP-1-EN-3-ONE DERIVATIVES; ANTIPROLIFERATIVE AND ANTIINFLAMMATORY AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030100538-A1 | Anticancer and inflammatory agents; diagnosis | SPEAR THERAPEUTICS LIMITED (GB) | 2003-05-29 | — | — | US | disclosed |
| EP-1284952-A1 | SUBSTITUTED CHALCONES AS THERAPEUTIC COMPOUNDS | Cancer Research Technology Limited (GB) | 2003-02-26 | — | — | EP | disclosed |
| WO-2001072680-A1 | SUBSTITUTED CHALCONES AS THERAPEUTIC COMPOUNDS | CANCER RESEARCH VENTURES LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100538-A1 | Anticancer and inflammatory agents; diagnosis | OXER1, MKI67, CCL2 | TNFRSF1A 178/4885MAPT 4611/4885ALDH1A1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.